GlassScriptPhysician profile
Scott Vincent Freeman
NPI 1821484072
$4,526.03
in general payments reported to CMS, 2019-2025
15 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.49 · 2020: $258 · 2021: $145 · 2022: $123 · 2023: $2,041 · 2024: $1,671 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,182 · Food and Beverage: $1,763 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,181.92 |
| Food and Beverage | $1,763.06 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,722.71 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Medtronic, INC. | $1,628.30 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Abbott Laboratories | $393.51 | 2020-2025 | Amplatzer Amulet |
| Boston Scientific Corporation | $273.31 | 2019-2024 | Angiojet Ultra 5000a |
| Asahi Intecc USA, INC. | $122.85 | 2022 | |
| Chiesi USA, INC. | $86.79 | 2023-2024 | Kengreal |
| Abiomed | $79.77 | 2024 | Impella |
| Penumbra, INC. | $48.00 | 2023 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $36.69 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $30.23 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.48 | 2024 | Jardiance |
| Terumo Medical Corporation | $21.26 | 2024 | Azur Cx Detachable |
| Philips North America LLC | $21.24 | 2025 | Extended Holter |
| Amgen INC. | $20.39 | 2024 | Repatha |
| W. L. Gore & Associates, INC. | $16.50 | 2024 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.